Henry Schein Inc. (HSIC) is well positioned to gain from its extensive global foothold and diverse channel mix. Yet, macroeconomic concerns are adversely impacting the company’s operational results. The stock carries a Zacks Rank #3 (Hold) currently. Henry Schein has strategically set up distribution centers worldwide to better serve customers and increase its operating efficiency. Apart from North America, the company has a presence in Australia and New Zealand as well as in emerging nations like China, Br ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zac ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What ar ...

Henry Schein (HSIC) recently extended its existing partnership with Special Olympics through 2025 to support health screening and education for its athletes at select events around the world. Through the collaboration, the company donates essential oral health and medical care products for the Special Olympics Healthy Athletes program in Australia, Canada, Germany, the United Kingdom and the United States. The donations to Special Olympics Healthy Athletes are an initiative of Henry Schein Cares, HSIC’s glo ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

Q1 2024 Earnings Conference Call Financial Results & Outlook May ...

财务数据和关键指标变化 - 2024年第一季度全球销售额为32亿美元,同比增长3.7%,内部销售额下降1.8% [29] - 2024年第一季度GAAP营业利润率为4.72%,同比下降101个基点;非GAAP营业利润率为7.11%,同比下降57个基点 [30] - 2024年第一季度GAAP净利润为9300万美元,每股摊薄收益0.72美元;非GAAP净利润为1.43亿美元,每股摊薄收益1.10美元 [31][32] - 2024年第一季度调整后EBITDA为2.55亿美元,与2023年第一季度持平 [33] 各条业务线数据和关键指标变化 牙科业务 - 2024年第一季度全球牙科销售额为19亿美元,同比增长0.8%,内部销售额下降2.9% [33][34] - 牙科耗材内部销售额下降3.7%,受到低价口罩销售下降的影响 [34] - 牙科设备内部销售额增长0.2%,北美增长2.9%,国际下降3.8% [34][35] - 牙科专科产品销售额为2.84亿美元,同比增长21.6%,主要由于并购带来的贡献 [35] 技术及增值服务业务 - 2024年第一季度全球技术及增值服务销售额为2.17亿美元,同比增长13.8%,内部销售额增长3.2% [36] - 北美内部销售增长2.3%,国际内部销售增长8.9%,主要由于云端解决方案Dentally的增长 [36] 医疗业务 - 2024年第一季度全球医疗销售额为10亿美元,同比增长7.3%,内部销售额下降0.7% [37] - 销售增长受到点护诊断产品强劲表现以及向更低价仿制药转移的影响 [37] 各个市场数据和关键指标变化 - 北美牙科耗材内部销售下降1%至2%,与行业整体表现一致 [86][87] - 国际市场牙科设备销售下降3.8%,但德国技术服务销售增长带动了整体设备销售 [34][35] - 医疗业务中,从急诊医疗向门诊医疗的转移趋势持续,但各类医疗程序数量相对稳定 [95][96] 公司战略和发展方向及行业竞争 - 公司正在积极执行BOLD+1战略计划,通过并购高增长高毛利业务来提升整体利润率 [10][11][53][54][55] - 公司在牙科专科产品如种植体、根管治疗和矫正等领域保持较高的市场份额,并通过新产品推出进一步扩大市场覆盖 [65][66][67][122][123] - 公司在医疗业务中持续获得新客户,并保持与现有大型客户的良好关系,未受到行业内其他分销商的激烈竞争影响 [95][96][97] 管理层对经营环境和未来前景的评论 - 公司对牙科和医疗行业的长期前景保持乐观,认为行业基本面稳定,虽然存在一些短期波动但不会对整体业务造成重大影响 [106][107][108][109][110] - 公司预计下半年销售增长将好于上半年,得益于新产品推出、并购带来的贡献以及从网络安全事件中的持续恢复 [120][121][122][123] - 公司对实现2024年非GAAP每股收益5-5.16美元的指引以及超过15%的调整后EBITDA增长目标保持信心 [41][42][43] 问答环节重要的提问和回答 问题1 **Jason Bednar 提问** 2024年第一季度毛利率大幅提升的原因是什么?这种高毛利率水平是否具有可持续性? [52][53][54][55] **Ronald South 和 Stanley Bergman 回答** 毛利率提升主要是由于业务结构的变化,公司近年来通过并购不断提升高毛利业务的占比,这些新业务在本季度的贡献较大。同时,公司在分销业务端也在逐步恢复毛利水平。预计未来这种高毛利的业务结构将持续,但具体水平还需视分销业务恢复情况而定。[53][54][55] 问题2 **John Stansel 提问** 技术及增值服务业务受到Change Healthcare网络安全事件的影响程度如何?公司如何帮助客户度过这一难关? [74][75][76] **Ronald South 和 Stanley Bergman 回答** Change Healthcare事件确实在3月份一定程度上拖累了技术业务的增长,但公司迅速采取了替代方案帮助客户恢复保险理赔的处理,并提供了其他支持,因此预计第二季度业务增长将恢复正常水平。公司认为这一事件对客户的现金流造成了一定压力,但通过提供帮助,已经帮助他们渡过难关。[75][76] 问题3 **Jeff Johnson 提问** 公司在北美牙科耗材业务中的表现如何?是否看到客户有向低价产品转移的趋势? [86][87][88][89][90] **Stanley Bergman 回答** 公司北美牙科耗材业务的表现基本与行业整体一致,价格相对稳定,公司产品线从高端到中低端都有涵盖,客户在选择上也比较平衡,没有明显的向低价产品转移的趋势。公司将继续关注那些更注重价格的散客群体的恢复。[88][89][90]

For the quarter ended March 2024, Henry Schein (HSIC) reported revenue of $3.17 billion, up 3.7% over the same period last year. EPS came in at $1.10, compared to $1.21 in the year-ago quarter. The reported revenue represents a surprise of -1.76% over the Zacks Consensus Estimate of $3.23 billion. With the consensus EPS estimate being $0.99, the EPS surprise was +11.11%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

Henry Schein, Inc. (HSIC) registered adjusted earnings per share (EPS) of $1.10 in the first quarter of 2024, down 9.1% from the year-ago period’s adjusted EPS. However, the metric exceeded the Zacks Consensus Estimate by 11.1%. Revenues in Detail Henry Schein reported net sales of $3.17 billion in the first quarter, up 3.7% year over year. The metric lagged the Zacks Consensus Estimate by 1.8%. The year-over-year upside reflects an internal sales decline of 1.8%. On a geographic basis, the company recorded ...

Henry Schein (HSIC) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $1.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this health care products maker would post earnings of $0.70 per share when it actually produced earnings of $0.66, delivering a surprise of -5.71%. Over the last four quar ...